Ranitidine |
رقم الكتالوجGC20026
One-Click Copy Product Info
|
رانيتيدين هو مضاد لمستقبلات الهيستامين H2 فعال بشكل فموي وانتقائي وفعال بتركيز IC50 يبلغ 3.3 مايكرومولار يثبط إفراز المعدة.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 66357-35-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ranitidine, an inhibitor of gastric acid secretion, competitively antagonizes histamine-induced increases in contraction frequency with a pA2 value of 7.2[1]. Ranitidine inhibits the activity of yeast sucrose enzyme in a non-competitive manner and causes structural changes, with an IC50 value of 2.2mM[2]. Ranitidine attenuates rotenone-induced apoptosis by inhibiting the phosphorylation of JNK and p38, as well as the activation of CASP, thereby preventing the cleavage of PARP and CASP3[3]. Ranitidine has been widely used to inhibit liver regeneration in rats after liver resection and to suppress the cell mitotic activity of liver cells[4].
In vitro, Ranitidine (100µM) pretreatment for 20 minutes significantly inhibited the death of rat cortical neuron cells induced by oxygen-glucose deprivation (OGD), and suppressed the activation of caspase 3 as well as the changes in the cytoskeleton[5]. Treatment with 0.1µM Ranitidine for 48 hours significantly inhibited the growth of Caco-2 cells and induced cell apoptosis[6].
In vivo, Ranitidine treatment via oral administration at a dose of 8mg/kg/day for 8 days significantly reduced the number of CD11b+ Ly6Chi cells in the spleen and bone marrow of BALB/c mice[7]. Oral administration of Ranitidine at a dose of 30mg/kg/day for 14 days significantly increased locomotor exploratory behavior and reduced anxiety-related behavior in a mouse model of gastrointestinal disease[8].
References:
[1] Daly M J, Humphray J M, Stables R. Some in vitro and in vivo actions of the new histamine H2-receptor antagonist, ranitidine[J]. British journal of pharmacology, 1981, 72(1): 49.
[2] Minai-Tehrani D, Ghaffari M, Sobhani-Damavandifar Z, et al. Ranitidine induces inhibition and structural changes in sucrase[J]. Journal of Enzyme Inhibition and Medicinal Chemistry, 2012, 27(4): 553-557.
[3] Park H J, Kim H J, Park H K, et al. Protective effect of histamine H2 receptor antagonist ranitidine against rotenone-induced apoptosis[J]. Neurotoxicology, 2009, 30(6): 1114-1119.
[4] Kanashima R, Nagasue N, Sakato K. Ranitidine as an inhibitor of liver regeneration[J]. The American journal of surgery, 1985, 149(2): 223-227.
[5] Malagelada C, Xifró X, Badiola N, et al. Histamine H2-receptor antagonist ranitidine protects against neural death induced by oxygen-glucose deprivation[J]. Stroke, 2004, 35(10): 2396-2401.
[6] Rajendra S, Mulcahy H, Patchett S, et al. The effect of H2 antagonists on proliferation and apoptosis in human colorectal cancer cell lines[J]. Digestive diseases and sciences, 2004, 49(10): 1634-1640.
[7] Vila-Leahey A, Oldford S A, Marignani P A, et al. Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice[J]. Oncoimmunology, 2016, 5(7): e1151591.
[8] Selvaraj D B, Vergil Andrews J F, Anusuyadevi M, et al. Ranitidine alleviates anxiety-like behaviors and improves the density of pyramidal neurons upon deactivation of microglia in the CA3 region of the hippocampus in a cysteamine HCl-induced mouse model of gastrointestinal disorder[J]. Brain Sciences, 2023, 13(2): 266.
| Cell experiment [1]: | |
Cell lines | SH-SY5Y cells |
Preparation Method | SH-SY5Y cells were cultured in DMEM medium supplemented with 10% fetal bovine serum, 100U/ml penicillin, and 100μg/ml streptomycin at 37°C with 5% CO2 and 95% saturated atmospheric humidity. Cells were seeded into 96-well microplates at a density of 5×103 cells/ml for 24h. In the presence or absence of rotenone (10μM; 24h), cells were treated with different concentrations (0, 1, 5, 10, 50, and 100μM) of Ranitidine for 24 hours, and cell viability was analyzed. |
Reaction Conditions | 0, 1, 5, 10, 50, and 100μM; 24h |
Applications | Ranitidine treatment significantly inhibited the cell death of SH-SY5Y cells induced by rotenone in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Female C57BL/6 mice |
Preparation Method | Female C57BL/6 mice (6 weeks old; 20-22g) were grouped in individually ventilated cages (IVC) and maintained under specific pathogen-free (SPF) conditions in an environment-controlled room (12h light/12h dark cycle, 21±2°C, 55% relative humidity) and had access to sterilized tap water and standard chow ad libitum. 2×105 E0771 cells in 100μl of Matrigel were injected subcutaneously into the mammary fat pad near the fourth nipple. The mice were given drinking water containing an 8mg/kg dose of Ranitidine every day for a period of 21 days. The volume of the tumor was determined by caliper measurements every second day using the equation volume = length × width2/2. |
Dosage form | 8mg/kg/day; 21 days; p.o. |
Applications | Ranitidine treatment significantly decreased tumor growth in mice with E0771 xenografts. |
References: | |
| Cas No. | 66357-35-5 | SDF | |
| Formula | C13H22N4O3S | M.Wt | 314.39 |
| الذوبان | DMSO : 63mg/mL | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1808 mL | 15.9038 mL | 31.8076 mL |
| 5 mM | 636.2 μL | 3.1808 mL | 6.3615 mL |
| 10 mM | 318.1 μL | 1.5904 mL | 3.1808 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)